Prevalence of metabolic syndrome among patients with Schizophrenia in Palestine

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Sweileh, Waleed M ^a   Zyoud, Sa'ed H ^a   Dalal, Salah A ^a   Ibwini, Sami ^a   Sawalha, Ansam F ^a   Ali, Iyad ^a  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

Author keywords

Metabolic syndrome; Palestine; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; HALOPERIDOL DECANOATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; THIORIDAZINE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; ZUCLOPENTHIXOL; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ADULT; AGE DISTRIBUTION; ARTICLE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; METABOLIC SYNDROME X; PALESTINE; PREVALENCE; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ARAB; CARDIOMETABOLIC RISK; FAMILY HISTORY; MENTAL HEALTH CENTER; MONOTHERAPY; PATIENT EDUCATION; COMORBIDITY; ETHNOLOGY; ISRAEL; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; ARABS; COMORBIDITY; FEMALE; HUMANS; ISRAEL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA;

MLCS; MLOWN;

EID: 84871562890     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-235     Document Type: Article

References (52)

1. Crismon ML, Dorson PG. Schizophrenia in Pharmacotherapy: A pathophysiologic approach 2002, 1219-1242. New York: McGraw-Hill, Dipiro J, Talbert RL, Yee G, Matzke GWells B, Posey L, 5.
2. van Os J, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001, 58(7):663-668. 10.1001/archpsyc.58.7.663, 11448373.
3. van Os J, Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645. 10.1016/S0140-6736(09)60995-8, 19700006.
4. McGrath J, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008, 30:67-76. 10.1093/epirev/mxn001, 18480098.
5. Sperling W, Biermann T. Mortality in patients with schizophrenia. Lancet 2009, 374(9701):1592. author reply 1592-3.
6. Tiihonen J, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627. 10.1016/S0140-6736(09)60742-X, 19595447.
7. Hennekens CH. Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease. CNS Spectr 2008, 13(6 Suppl 10):9-10.
8. Kelly DL, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 71(3):304-311.
9. Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol 2005, 19(6 Suppl):84-93. 10.1177/0269881105058375, 16280341.
10. Haffner SM, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992, 41(6):715-722. 10.2337/diabetes.41.6.715, 1587398.
11. Sandhofer A, et al. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 2007, 37(2):109-116. 10.1111/j.1365-2362.2007.01751.x, 17217376.
12. Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006, 49(12):2837-2846.
13. Golley RK, et al. Comparison of metabolic syndrome prevalence using six different definitions in overweight pre-pubertal children enrolled in a weight management study. Int J Obes (Lond) 2006, 30(5):853-860.
14. De Hert M, Peuskens B, van Winkel R. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res 2006, 88:222-226. 10.1016/j.schres.2006.07.025, 16996250.
15. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66(1):51-57. 10.1016/S0920-9964(02)00498-X, 14693352.
16. Lyketsos CG, et al. Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics 2002, 43(1):24-30. 10.1176/appi.psy.43.1.24, 11927754.
17. ATPIII Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421. ATPIII.
18. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491):1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
20. ADA Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5-S20. ADA.
21. Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44(3):720-732. 10.1016/j.jacc.2004.07.001, 15358046.
22. Alberti KG, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
23. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab 2004, 89(6):2590-2594. 10.1210/jc.2004-0339, 15181028.
24. Kraja AT, et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab 2005, 2:17.
25. Rakugi H, Ogihara T. The metabolic syndrome in the asian population. Curr Hypertens Rep 2005, 7(2):103-109. 10.1007/s11906-005-0082-4, 15748533.
26. Abdul-Rahim HF, et al. The metabolic syndrome in the West Bank population: an urban-rural comparison. Diabetes Care 2001, 24(2):275-279. 10.2337/diacare.24.2.275, 11213878.
27. Sirdah MM NA, Laham A, Abu Ghali AS. Prevalence of metabolic syndrome and associated socioeconomic and demographic factors among Palestinian adults (20-65 years) at the Gaza Strip. Diabetes Metab Syndr 2011, 5(2):93-97. 10.1016/j.dsx.2012.02.024, 22813411.
28. Yasein N, Masa'd D. Metabolic syndrome in family practice in Jordan: a study of high-risk groups. East Mediterr Health J 2011, 17(12):943-948.
29. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
30. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007, 68(Suppl 1):20-27.
31. Allison DB, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156(11):1686-1696.
32. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64(6):663-667. 10.4088/JCP.v64n0607, 12823080.
33. Xiang YT, et al. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008, 46(5):245-251.
34. Joseph D, et al. Pharmacotherapy: A pathophysiologic approach 2011, 1147-1172. New York, NY: The McGraw - Hill Companies, 8.
35. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000, 19(22):3127-3131. 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M, 11113947.
36. Cohn T, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49(11):753-760.
37. De Hert M, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006, 2:14. 10.1186/1745-0179-2-14, 1533826, 16803620.
38. De Hert MA, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006, 83(1):87-93. 10.1016/j.schres.2005.12.855, 16481149.
39. Hagg S, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006, 21(2):93-98. 10.1097/01.yic.0000188215.84784.17, 16421460.
40. McEvoy JP, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32. 10.1016/j.schres.2005.07.014, 16137860.
41. Suvisaari JM, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68(7):1045-1055. 10.4088/JCP.v68n0711, 17685741.
42. Hatata H, et al. Risk of metabolic syndrome among Egyptian patients with schizophrenia. Current Psychiatry 2009, 16(1):85-95.
43. Shahda M, Elsayed O, El-Boraie A. Study of the prevalence of metabolic syndrome among psychiatric patients and its correlation with diagnosis and medications Egypt. J. Psychiatry 2010, 31(2):17-24.
44. De Hert M, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008, 101(1-3):295-303.
45. Meyer JM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008, 101(1-3):273-286.
46. Correll CU, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89(1-3):91-100. 2718048, 17070017.
47. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 2005, 48(2):215-221. 10.1007/s00125-004-1641-y, 15688206.
48. Thakore JH, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26(1):137-141. 10.1038/sj.ijo.0801840, 11791159.
49. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1(8636):495.
50. Wilson PW, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072. 10.1161/CIRCULATIONAHA.105.539528, 16275870.
51. Wilson PW, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847. 10.1161/01.CIR.97.18.1837, 9603539.
52. Matheny MM, Mc P, Glasser A. Systematic Review of Cardiovascular Disease Risk Assessment Tools [Internet] 2011, Rockville (MD): Agency for Healthcare Research and Quality (US), (Evidence Syntheses/Technology Assessments, No. 85.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK56166/.